Micropos Medical develops and provides technologies that enhance the precision in radiotherapy of cancer. The first product, RayPilot system, is an electromagnetic positioning system that enables real time information of the target localization for a fast and objective set-up and for continuous monitoring during the treatment. RayPilot HypoCath, the new member of the RayPilot family, is designed like an ordinary urinary catheter with intergrated RayPilot transmitter technology. An alternative without any surgical intervention with same features as the original RayPilot to enhance clinical confidence when performing hypofractionated/SBRT prostate cancer treatment protocols for any linacs.
The RayPilot system together with RayPilot HypoCath are CE certified for prostate use but has the potential for future use in other tumor areas.
By using RayPilot, our ambition is to enable more accurate treatment, reduce undesired side effects, and get higher patient throughput which benefits both patients and healthcare providers. Micropos Medical AB (publ) is a company listed on the Swedish stock list Spotlight Stock Market (former AktieTorget) under the stock ticker MPOS.